All over the internet, just search for orforglipron.
An organic molecule will be easier to produce, ship and store vs a peptide. A once daily pill is also a lot easier for patients vs an injection.
Here’s Lilly’s press release
4 Likes
This is the future! People will take them like statins, I suspect. The next big blockbuster drug for Lilly.
3 Likes
I agree…their stock is up 14-15% today. It’s apparently licensed to them by a small Japanese Pharma company who developed it. I bet they are celebrating as well. 
1 Like
Definitely an exciting development…
The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.
Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. Industry analysts expect the drug to win approval sometime next year and to eventually become a major blockbuster. Eli Lilly is not expected to announce a price for the drug until after it wins approval.
Full article:
Also, does not have the dosing restrictions of Rybelsus, (Novo oral GLP-1) Required to take in morning on empty stomach with 4 oz water and wait 30 min for any food or liquid. Goodbye morning breakfast or coffee. Orforglipon has no such limitations. I can buy at pharmacy here in Spain: RYBELSUS 14 MG 30 COMPRIMIDOS 132,77 Euros. Only approved for diabetes, but many using for weight loss.
3 Likes
First source I’ve found of it: https://biolongevitylabs.com/product/biozapetite
Very expensive, and it’s not out yet but I’m on the email list of Hunter Williams some guy who talks about peptides and biohacking.
If they have access to it, expect it to start showing up in the various gray markets soon and hopefully at a cheaper price. I don’t actually buy from this company as they are exorbitantly overpriced.
I’ll post the text from the email advertising this as I found it to be a good read on the molecule:
For years, people have been chasing the “holy grail” of weight loss and glucose control without injections.
We’ve witnessed the meteoric rise of semaglutide, tirzepatide, and retatrutide.
But behind the scenes, researchers have been working on a small-molecule pill that acts like a GLP-1 receptor agonist.
That drug is orforglipron, and it represents a completely new era.
Unlike peptide-based GLP-1s that require refrigeration and injections, orforglipron is a stable, easy-to-produce pill that is highly bioavailable.
Chugai Pharmaceutical originally discovered it, and Eli Lilly quickly licensed it in 2018.
Since then, it’s moved through Phase 1, Phase 2, and now Phase 3 trials with remarkable results.
For clinicians and researchers like us, this is one of the most exciting metabolic drugs we’ve seen in decades.How Orforglipron Works
Mechanistically, orforglipron is fascinating.
It’s a partial agonist of the GLP-1 receptor, but it’s Gs-biased, meaning it drives the cAMP pathway (insulin release, glucagon suppression, appetite regulation) while barely engaging β-arrestin.
In plain English, why does that matter?
Lower β-arrestin activity could mean less receptor desensitization over time.
In other words, orforglipron might hold its effect longer without the rapid desensitization some patients see on peptide GLP-1s.
It binds with high affinity (Ki ~1 nM), and in preclinical models, even low receptor occupancy was enough to mimic the full GLP-1 effect.
This resulted in stronger insulin release when glucose is high, slower gastric emptying, reduced hunger signals, and decreased food intake.
In short, it activates the same pathways that have made semaglutide and tirzepatide world-famous.
But this comes in a pill form, with a slightly different signaling profile that could offer unique advantages.What the Studies Show (Part 1 – Obesity)
In the NEJM Phase 2 obesity trial (Wharton et al., 2023), adults with obesity or overweight were randomized to placebo or daily orforglipron (12–45 mg). The results after 36 weeks were jaw-dropping.
- Placebo: –2.3% weight loss
- Orforglipron 12 mg: –9.4%
- Orforglipron 24 mg: ~–12%
- Orforglipron 45 mg: –14.7%
Even more impressive, 46–75% of participants hit ≥10% total body weight reduction, depending on dose.
And every prespecified cardiometabolic risk factor (blood pressure, waist circumference, lipid markers) improved significantly compared to placebo.
These numbers put orforglipron in the same league as semaglutide 2.4 mg weekly.
And remember, this was achieved with a daily pill, no injections, no storage headaches, and no reconstitution needed.What the Studies Show (Part 2 – Diabetes)
In the Lancet Phase 2 T2DM trial (Frias et al., 2023), 383 patients with type 2 diabetes (mean baseline HbA1c ~8.1%) received orforglipron (3–45 mg), dulaglutide 1.5 mg weekly, or placebo.
By 26 weeks:
- Placebo: –0.43% HbA1c, –2.2 kg weight loss
- Dulaglutide: –1.10% HbA1c, –3.9 kg weight loss
- Orforglipron (high dose): –2.10% HbA1c, –10.1 kg weight loss
As you can see, it resulted in nearly double the glucose reduction and weight loss of dulaglutide, a standard injectable GLP-1. Over 80% of patients on orforglipron achieved HbA1c <7%.
And in Phase 3 ACHIEVE-1 (2025):- HbA1c dropped –1.3% to –1.6% at 40 weeks.
- Body weight decreased by 4.7% to –7.9%.
- No hepatic safety signal.
What Benefits Can You Expect?
The benefits of orforglipron fall into three main categories:
- Appetite suppression and weight loss – Clinical data shows ~10–15% body weight reduction in under a year. Unlike injectables that can cause nausea, many patients report a cleaner “I’m just not hungry” feeling.
- Improved glycemic control – HbA1c reductions of up to –2% rival the most powerful GLP-1s. It improves fasting glucose, post-prandial spikes, and overall insulin sensitivity.
- Cardiometabolic improvements – Lower blood pressure, improved lipid profiles, reduced waist circumference
When combined with resistance training, protein-sufficient nutrition, and hormone optimization, the body recomposition potential is enormous.
Less fat, more muscle preserved, improved labs, and better overall metabolic resilience.Dosing & Titration
Orforglipron is long-acting, with a 29–49 hour half-life. That means one capsule a day provides steady coverage.
In trials, patients started as low as 1–3 mg daily and titrated up over weeks. Doses of 12–36 mg daily are the sweet spot for weight and glucose efficacy, with 45 mg being the highest tested.
For research purposes, our BioZapetite capsules at BioLongevity Labs will deliver 6 mg per cap. Here’s what I would recommend based on my personal experience so far:
- Start at 6 mg daily (1 cap).
- After 1–2 weeks, increase to 12 mg (2 caps).
- Continue titrating upward every 2–3 weeks as needed, depending on tolerance and research objectives.
The key is the slow buildup.
GI events (nausea, diarrhea, dyspepsia) are most common early on. Careful titration smooths the ride.My Personal Experience
In our livestream last night, I shared my first days on BioZapetite.
Day 1, I took 12 mg in the morning.
Nothing dramatic at first. But by mid-afternoon, I felt a wave of satiety that shut off food noise.
Dinner rolled around and I wasn’t forcing myself to resist food.
I just wasn’t interested.
Unlike semaglutide or tirzepatide, the appetite suppression didn’t cause nausea.
There also was no stomach pain.
It was clean, mental appetite suppression.
Over the next days, that feeling stabilized.
By Day 3 or 4, it hit earlier in the day, and I noticed a tighter control on caloric intake without feeling deprived.
For someone who’s experimented with every GLP-1 in the book, this felt as good if not better than tirzepatide.Why This Matters
Obesity and diabetes are epidemics of untold proportions.
Billions of people worldwide are at risk, and while injectables have been a revolution, they aren’t accessible to everyone.
Orforglipron represents a democratization of GLP-1 therapy.
As a pill, scalable to produce, stable without refrigeration, and affordable, it could reach far more people than injectables ever will.
But beyond accessibility, it also comes down to quality of life.
No needles. No storage hassles. Just a pill you can take once a day and move on with your life.
For biohackers, clinicians, and researchers at the tip of the spear, this is a molecule worth paying attention to.Coming Soon to BioLongevity Labs
At BioLongevity Labs, our mission has always been to put the most advanced molecules into the hands of researchers.
Orforglipron (branded as BioZapetite) is next.
We’ll soon be offering 6 mg capsules for research use only.
It’s the perfect entry point for titration, allowing flexibility to scale from 6 mg up to 12, 18, 24 mg and beyond as needed.
So stay tuned. BioZapetite is coming very soon to BioLongevity Labs.
And when it does, it’s going to change the landscape for researchers worldwide.Further Reading
- Wharton S, et al. NEJM 2023 — Phase 2 trial of orforglipron in obesity.https://pubmed.ncbi.nlm.nih.gov/37351564/#:~:text=Results%3A%20%20A%20total%20of,improvement%20in%20all%20prespecified%20weight
- Frias JP, et al. Lancet 2023 — Phase 2 multicentre dose-response trial in type 2 diabetes.https://cardiometabolicforum.com/publications/99/efficacy-and-safety-of-oral-orforglipron-in-patients-with-type-2-diabetes-a-multicentre-randomised-dose-response-phase-2-study#:~:text=to%20%E2%88%9210,were%20observed%20with
- Pratt E, et al. Diabetes Obes Metab 2023 — Phase 1b multiple ascending dose trial.https://pubmed.ncbi.nlm.nih.gov/37264711/#:~:text=common%20adverse%20events%20were%20gastrointestinal,5%20kg%20with%20placebo
- Eli Lilly Press Release (2025) — Phase 3 ACHIEVE-1 results.https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-3-trial-302430985.html#:~:text=A1C%20reduction%20from%20baseline%C2%A0of%208.0
- Ma X, et al. Diabetes Therapy 2024 — Food-effect pharmacokinetics of orforglipron.https://link.springer.com/article/10.1007/s13300-024-01554-1#:~:text=Study%C2%A0A%20included%2012%20participants%20,were%20reported%20in%20either%20study
- Sloop KW, et al. Sci Transl Med 2024 — Mechanistic pharmacology of orforglipron.https://pubmed.ncbi.nlm.nih.gov/39693407/#:~:text=%5B%5E%7B125%7DI%5DGLP,Moreover%2C%20in%20a%20model%20where
- Briseño-Díaz P, et al. Sci Pharm 2025 — Review of small-molecule GLP-1 receptor agonists.https://www.mdpi.com/2218-0532/93/2/26#:~:text=In%20Phase%202%20studies%2C%20orforglipron,those%20on%20the%20highest%20dose
- Sidik S. Nature News 2023 — “Beyond Ozempic”: small-molecule GLP-1s and market outlook.https://www.nature.com/articles/d41586-023-02092-9?error=cookies_not_supported&code=81bcc1b5-e00b-4940-bd8f-ebe2b2173556#:~:text=Two%20new%20drugs%20for%20treating,bar%20for%20pharmacological%20obesity%20treatment
2 Likes
It has arrived in the research chemical world.
https://www.peptidesciences.com/orforglipron-6mg-capsules
2 Likes
It looks like a good mid-range product, but for those who need to lose 30, 40, 50 or more lbs it won’t do the trick.
Note they compare it to Dulaglutide, which is not as good as semaglutide for weight loss.
Semaglutide, is the poorest performer of the top 3 GLP1’s, even with the help of Cagrilintide it is still not as effective as the top 2.
Reta is still the king.
retatrutide leads with about 24% average weight loss at 48 weeks, tirzepatide is estimated to achieve 20.5% at 48 weeks, and semaglutide delivered around 15% at 48 weeks (though the upcoming 7.2mg dose showed up to 18% weight loss at 48 weeks).
There is a huge market for oral weight loss products, no doubt about that. I do wonder if it would be a reasonable maintenance product for those who have lost weight, one way or the other.
Personally I prefer a once a week shot and not be concerned about taking another pill on time.
2 Likes
Yes, with this product, Lilly has 3 tiers of weight loss offerings:
- orforglipron targets those that have an extra 10 to 20 lbs to lose
- tirzepatide for those that have at least 50 lbs to lose
- retatrutide for those that have at least 80 lbs to lose.
They will be priced accordingly, expect orforglipron to be much cheaper than the other 2.
Press release made today based on top line results :
Improvements in A1c, and clinically meaningful benefits across key cardiovascular risk factors, including non-HDL cholesterol, systolic blood pressure and triglycerides. Hs-crp was also reduced by 50% on the highest dose.
3 Likes
- Eli Lilly on Tuesday said its daily obesity pill succeeded in another late-stage trial, helping patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels.
- The company now has the full clinical trial data required to start filing for approvals of the drug for chronic weight management with global regulators.
- The rate of side effects and treatment discontinuations in the study, called ATTAIN-2, appeared to be generally consistent with two recent phase three trials on the pill, called orforglipron.
1 Like
I suspect the major potential limitation for widespread use will be tolerability. GLP-1-only drugs (semaglutide) tend to have more side effects for most people compared to dual agonists (tirzepatide) or tri-agonists (retatrutide). Orforglipron seems to be similar in tolerability to semaglutide, which is ok but not great.
4 Likes
I think of it as a maintenance product. I’m down to use this once I run out of tirzepatide.
2 Likes